Telix Pharmaceuticals Securities Class Action (NASDAQ: TLX)

Telix Pharmaceuticals Securities Fraud Investigation

Contact UsFree Case Evaluation

"*" indicates required fields

First Name*

Last Name*

Email Address*

Phone Number*

Practice Area

City*

State*

Please describe your potential case or matter.**

By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.

Practice Area: Securities Fraud & Investor Protection

Ticker Symbol: NASDAQ: TLX

Investigation Deadline: January 9, 2026

A class action lawsuit was filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the “Class Period”).

Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, contact Berger Montague.

Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company developing diagnostic and therapeutic radiopharmaceutical products.

During the Class Period, defendants allegedly made false or misleading statements and/or failed to disclose that the Company had overstated its progress with prostate cancer therapeutic candidates and exaggerated the quality of its supply chain and partners. As a result, statements regarding the Company’s business, operations, and prospects were allegedly false, misleading, or lacked a reasonable basis. According to the complaint, when the true state of the Telix’s business became public, investors suffered significant losses.

If you are a Telix investor and would like to learn more about this action, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.